Aberrant DNA methylation of ESR1 and P14ARF genes could be useful as prognostic indicators in osteosarcoma

OncoTargets and Therapy

Volumn 6, Issue , 2013, Pages 713-723

  Sonaglio, Viviane ^a   de Carvalho, Ana C ^b   Toledo, Silvia R C ^b   Salinas Souza, Carolina ^b   Carvalho, André L ^c   Petrilli, Antonio S ^b   De Camargo, Beatriz ^d   Vettore, André L ^b  

^a A C CAMARGO CANCER CENTER   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c BARRETOS CANCER HOSPITAL   (Brazil)

^d INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Dna methylation; Esr1; Hypermethylation; Osteosarcoma; P14arf

Indexed keywords

MOLECULAR MARKER;

ADOLESCENT; ADULT; AIM1 GENE; APC GENE; ARTICLE; BONE BIOPSY; CALCA GENE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER PROGNOSIS; CCNA1 GENE; CDH1 GENE; CDKN2A GENE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DAPK GENE; DNA METHYLATION; EPIGENETICS; ESR1 GENE; FEMALE; GENE; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC CORRELATION; GENETIC SELECTION; GSTP1 GENE; HIC1 GENE; HUMAN; HUMAN TISSUE; MALE; METASTASIS; MLH1 GENE; NECROSIS; OSTEOSARCOMA; OVERALL SURVIVAL; P14ARF GENE; PATHOLOGY; PREOPERATIVE TREATMENT; PROMOTER REGION; RAR BETA GENE; RASSF1A GENE; RB1 GENE; SCHOOL CHILD; SFRP1 GENE; SOCS1 GENE; SURVIVAL TIME; THBS1 GENE;

EID: 84879155482     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S44918     Document Type: Article

References (54)

1. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res. 2009;152:3-13.
2. Jaffe N. Adjuvant chemotherapy in osteosarcoma: An odyssey of rejection and vindication. In: Jaffe N, Bielack SS, Bruland ÃS, editors. Pediatric and Adolescent Osteosarcoma, Cancer Treatment and Research. New York: Springer; 2009:219-238.
3. Ferrari S, Palmerini E. Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol. 2007;19(4): 341-346.
4. Chou AJ, Geller DS, Gorlick R. Therapy for osteosarcoma: where do we go from here? Paediatr Drugs. 2008;10(5):315-327.
5. Buddingh EP, Anninga JK, Versteegh MI, et al. Prognostic factors in pulmonary metastasized high-grade osteosarcoma. Pediatr Blood Cancer. 2010;54(2):216-221.
6. Lewis IJ, Nooij MA, Whelan J, et al; MRC BO06 and EORTC 80931 collaborators; European Osteosarcoma Intergroup. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst. 2007;99(2): 112-128.
7. Mankin HJ, Hornicek FJ, Rosenberg AE, Harmon DC, Gebhardt MC.Survival data for 648 patients with osteosarcoma treated at one institution. Clin Orthop Relat Res. 2004;(429):286-291.
8. Bielack S, Carrle D, Jost L; ESMO Guidelines Working Group. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19 Suppl 2:ii94-ii96.
9. Petrilli AS, de Camargo B, Filho VO, et al; Brazilian Osteosarcoma Treatment Group Studies III and IV. Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival. J Clin Oncol. 2006;24(7):1161-1168.
10. Sakamoto A, Iwamoto Y. Current status and perspectives regarding the treatment of osteo-sarcoma: chemotherapy. Rev Recent Clin Trials. 2008;3(3):228-231.
11. Batanian JR, Cavalli LR, Aldosari NM, et al. Evaluation of paediatric osteosarcomas by classic cytogenetic and CGH analyses. Mol Pathol. 2002;55(6):389-393.
12. Gorlick R. Current concepts on the molecular biology of osteosarcoma. Cancer Treat Res. 2009;152:467-478.
13. Lim G, Karaskova J, Beheshti B, et al. An integrated mBAND and submegabase resolution tiling set (SMRT) CGH array analysis of focal amplification, microdeletions, and ladder structures consistent with breakage-fusion-bridge cycle events in osteosarcoma. Genes Chromosomes Cancer. 2005;42(4):392-403.
14. Selvarajah S, Yoshimoto M, Maire G, et al. Identification of cryptic microaberrations in osteosarcoma by high-definition oligonucleotide array comparative genomic hybridization. Cancer Genet Cytogenet. 2007;179(1):52-61.
15. Cui Q, Jiang W, Guo J, et al. Relationship between hypermethylated MGMT gene and osteosarcoma necrosis rate after chemotherapy. Pathol Oncol Res. 2011;17:587-591.
16. Oh JH, Kim HS, Kim HH, Kim WH, Lee SH. Aberrant methylation of p14ARF gene correlates with poor survival in osteosarcoma. Clin Orthop Relat Res. 2006;442:216-222.
17. Gorlick R, Anderson P, Andrulis I, et al. Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res. 2003;9(15):5442-5453.
18. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349(21): 2042-2054.
19. Geiman TM, Robertson KD. Chromatin remodeling, histone modifications, and DNA methylation-how does it all fit together? J Cell Biochem. 2002;87(2):117-125.
20. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3(6):415-428.
21. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res. 2001;61(8): 3225-3229.
22. Tsuchiya T, Sekine K, Hinohara S, Namiki T, Nobori T, Kaneko Y. Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genet Cytogenet. 2000;120(2):91-98.
23. Benassi MS, Molendini L, Gamberi G, et al. Involvement of INK4A gene products in the pathogenesis and development of human osteosarcoma. Cancer. 2001;92(12):3062-3067.
24. Lim S, Yang MH, Park JH, et al. Inactivation of the RASSF1A in osteosarcoma. Oncol Rep. 2003;10(4):897-901.
25. Patiño-Garcia A, Piñeiro ES, Díez MZ, Iturriagagoitia LG, Klüssmann FA,Ariznabarreta LS. Genetic and epigenetic alterations of the cell cycle regulators and tumor suppressor genes in pediatric osteosarcomas. J Pediatr Hematol Oncol. 2003;25(5):362-367.
26. Hou P, Ji M, Yang B, et al. Quantitative analysis of promoter hypermethylation in multiple genes in osteosarcoma. Cancer. 2006;106(7): 1602-1609.
27. Vidal DO, Paixão VA, Brait M, et al. Aberrant methylation in pediatric myelodysplastic syndrome. Leuk Res. 2007;31(2):175-181.
28. Eads CA, Lord RV, Wickramasinghe K, et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res. 2001;61:3410-3418.
29. Carvalho AL, Jeronimo C, Kim MM, et al. Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma. Clin Cancer Res. 2008;14:97-107.
30. Harden SV, Tokumaru Y, Westra WH, et al. Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin Cancer Res. 2003;9:1370-1375.
31. Jeronimo C, Usadel H, Henrique R, et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst. 2001;93:1747-1752.
32. Hoque MO, Feng Q, Toure P, et al. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol. 2006;24:4262-4269.
33. Lehmann U, Langer F, Feist H, et al. Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol. 2002;160:605-612.
34. Weisenberger DJ, Siegmund KD, Campan M et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38:787-793.
35. de Carvalho F, Colleoni GW, Almeida MS, Carvalho AL, Vettore AL. TGFbetaR2 aberrant methylation is a potential prognostic marker and therapeutic target in multiple myeloma. Int J Cancer. 2009;125(8): 1985-1991.
36. Brabender J, Usadel H, Danenberg KD, et al. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival. Oncogene. 2001;20(27):3528-3532.
37. Eads CA, Danenberg KD, Kawakami K, et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. 2000;28(8):E32.
38. Ray ME, Wistow G, Su YA, Meltzer PS, Trent JM. AIM1, a novel non-lens member of the betagamma-crystallin superfamily, is associated with the control of tumorigenicity in human malignant melanoma. Proc Natl Acad Sci U S A. 1997;94(7):3229-3234.
39. Begum S, Brait M, Dasgupta S, et al. An epigenetic marker panel for detection of lung cancer using cell-free serum DNA. Clin Cancer Res. 2011;17(13):4494-4503.
40. Brait M, Begum S, Carvalho AL, et al. Aberrant promoter methylation of multiple genes during pathogenesis of bladder cancer. Cancer Epidemiol Biomarkers Prev. 2008;17(10):2786-2794.
41. Loyo M, Brait M, Kim MS, et al. A survey of methylated candidate tumor suppressor genes in nasopharyngeal carcinoma. Int J Cancer. 2011;128(6):1393-1403.
42. Tarkkanen M, Elomaa I, Blomqvist C, et al. DNA sequence copy number increase at 8q: a potential new prognostic marker in high-grade osteosarcoma. Int J Cancer. 1999;84(2):114-121.
43. Fletcher JA, Gebhardt MC, Kozakewich HP. Cytogenetic aberrations in osteosarcomas. Nonrandom deletions, rings, and double-minute chromosomes. Cancer Genet Cytogenet. 1994;77(1):81-88.
44. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell. 1995;83(6):993-1000.
45. Kamijo T, Zindy F, Roussel MF, et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997;91(5):649-659.
46. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci U S A. 1998;95(14): 8292-8297.
47. Robertson KD, Jones PA. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol Cell Biol. 1998;18(11): 6457-6473.
48. Sailasree R, Abhilash A, Sathyan KM, Nalinakumari KR, Thomas S,Kannan S. Differential roles of p16INK4A and p14ARF genes in prognosis of oral carcinoma. Cancer Epidemiol Biomarkers Prev. 2008;17(2):414-420.
49. Stossi F, Barnett DH, Frasor J, Komm B, Lyttle CR, Katzenellenbogen BS. Transcriptional profiling of estrogen-regulated gene expression via estrogen receptor (ER) alpha or ERbeta in human osteosarcoma cells: distinct and common target genes for these receptors. Endocrinology. 2004;145(7):3473-3486.
50. Lima F, Vico L, Lafage-Proust MH, van der Saag P, Alexandre C, Thomas T. Interactions between estrogen and mechanical strain effects on U2OS human osteosarcoma cells are not influenced by estrogen receptor type. Bone. 2004;35(5):1127-1135.
51. Bord S, Horner A, Beavan S, Compston J. Estrogen receptors alpha and beta are differentially expressed in developing human bone. J Clin Endocrinol Metab. 2001;86(5):2309-2314.
52. Susman E. Osteosarcoma: Where Research Is Heading. Skeletal Complications of Malignancy Symposium. Oncol Times. 2005;27(18): 37-38.
53. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet. 1994;7(4):536-540.
54. Müller HM, Widschwendter A, Fiegl H, et al. DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res 2003;63:7641-7645.